Aldeyra Therapeutics, Inc. (FRA:137)
Germany
· Delayed Price · Currency is EUR 4.011
-0.145 (-3.49%)
At close: Dec 5, 2025
Aldeyra Therapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Net Income | -43.19 | -55.85 | -37.54 | -62.02 | -57.78 | -37.55 | Upgrade
|
| Depreciation & Amortization | 0.25 | 0.25 | 0.26 | 0.26 | 0.26 | 0.06 | Upgrade
|
| Other Amortization | 0.27 | - | - | - | - | - | Upgrade
|
| Asset Writedown & Restructuring Costs | - | - | - | - | - | 1.75 | Upgrade
|
| Loss (Gain) From Sale of Investments | -1.57 | -1.67 | -0.01 | -0.05 | - | -0.09 | Upgrade
|
| Stock-Based Compensation | 6.26 | 7.97 | 5.75 | 8.29 | 7.11 | 7.08 | Upgrade
|
| Other Operating Activities | 0.21 | 0.18 | 0.35 | 0.33 | 0.41 | 0.09 | Upgrade
|
| Change in Accounts Payable | -0.17 | -1.16 | 1.2 | -0.89 | 0.64 | -0.43 | Upgrade
|
| Change in Unearned Revenue | - | - | 6 | - | - | - | Upgrade
|
| Change in Other Net Operating Assets | -2.14 | 7.07 | -6.34 | -2.56 | 6.8 | -8.4 | Upgrade
|
| Operating Cash Flow | -40.08 | -43.21 | -30.33 | -56.64 | -42.56 | -37.49 | Upgrade
|
| Capital Expenditures | - | - | - | -0.02 | -0.01 | - | Upgrade
|
| Investment in Securities | 30.17 | -44.92 | 30 | -29.94 | - | 29.02 | Upgrade
|
| Investing Cash Flow | 30.17 | -44.92 | 30 | -29.95 | -0.01 | 29.02 | Upgrade
|
| Long-Term Debt Repaid | - | -0.29 | -1.04 | - | - | - | Upgrade
|
| Total Debt Repaid | -0.29 | -0.29 | -1.04 | - | - | - | Upgrade
|
| Net Debt Issued (Repaid) | -0.29 | -0.29 | -1.04 | - | - | - | Upgrade
|
| Issuance of Common Stock | 1.47 | 0.39 | 0.31 | 1.22 | 194.5 | 41.9 | Upgrade
|
| Repurchase of Common Stock | - | - | -0.53 | - | - | - | Upgrade
|
| Other Financing Activities | -0.05 | -0.27 | - | - | - | - | Upgrade
|
| Financing Cash Flow | 1.13 | -0.17 | -1.27 | 1.22 | 194.5 | 41.9 | Upgrade
|
| Net Cash Flow | -8.78 | -88.3 | -1.6 | -85.37 | 151.93 | 33.43 | Upgrade
|
| Free Cash Flow | -40.08 | -43.21 | -30.33 | -56.65 | -42.56 | -37.49 | Upgrade
|
| Free Cash Flow Per Share | -0.67 | -0.73 | -0.51 | -0.97 | -0.79 | -1.10 | Upgrade
|
| Cash Interest Paid | 1.69 | 1.75 | 1.7 | 1.34 | 1.34 | 1.39 | Upgrade
|
| Levered Free Cash Flow | 15.58 | -17.06 | -27.62 | 92.19 | -123.6 | -20.28 | Upgrade
|
| Unlevered Free Cash Flow | 16.77 | -15.86 | -26.32 | 93.25 | -122.51 | -19.09 | Upgrade
|
| Change in Working Capital | -2.31 | 5.91 | 0.86 | -3.44 | 7.44 | -8.83 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.